Previous 10 | Next 10 |
Lantern Pharma (LTRN) has priced its public offering of 4,285,715 common shares at $14.00/share, for gross proceeds of $60M.Underwriters' over-allotment is an additional 642,856 shares. ThinkEquity is acting as sole book-running manager and Colliers Securities is as co-manager for the offerin...
Lantern Pharma Announces Pricing of $60 Million Public Offering PR Newswire DALLAS , Jan. 14, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR ® artificial intelligence ("A.I.") platfo...
Clinical-stage biopharma company Lantern Pharma (LTRN) announces that it will be launching the development of its antibody drug conjugate ((ADC)) program through an evaluation and potential development agreement with Califia Pharma along with other key internal development and compu...
Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through A...
Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma DALLAS , Dec. 17, 2020 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its p...
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers DALLAS , Dec. 15, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN ), a clini...
The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion. Lock-up periods will be expiring for nine companies. For further details see: U.S. IPO Week Ahead: D...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Lantern works at the intersection of Artificial Intelligence, Genomics, and Machine Learning. It discovers novel oncology assets using its platform. The company is very early stage, but it could be a nice diversification asset for investors. For further details see: Lant...
Lantern Pharma Inc. (LTRN) Q3 2020 Results Conference Call October 29, 2020 04:00 PM ET Company Participants Marek Ciszewski - Director, IR Panna Sharma - President and CEO David Margrave - CFO Conference Call Participants Kyle Bauser - Colliers John Vandermosten - Zacks Small Cap Presentatio...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...